A number of serum biomarkers, including human epididymis protein 4 (HE4) [34] and cancer antigen 125 (CA-125) [35] have been studied in endometrial cancer, but their low diagnostic performance limits their clinical utility. This evidence concerns the gene WFDC2 and endometrial cancer.